Best Health Care Grants in American Samoa

The FY26 Pancreatic Cancer Research Program (PCARP) Translational Research Partnership Award encourages collaboration among clinicians and scientists to expedite the clinical application of innovative pancreatic cancer research. A minimum of two Principal Investigators is required, with one designated as the Initiating PI. This award supports preliminary data collection and various research methodologies, excluding large-scale clinical trials, to enhance pancreatic cancer understanding and treatment.

This funding opportunity invites applications for investigator-initiated clinical trials focused on complementary and integrative health interventions delivered remotely or via mobile health technologies. The trials must be fully powered, with no in-person contact, and require justification for this approach. Preliminary data on feasibility and safety must be provided, alongside evidence of clinical benefit. A Plan for Enhancing Diverse Perspectives is mandatory for submission. Key deadlines range from February 2024 to June 2026.

The NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01) invites applications for clinical trials focusing on complementary and integrative health approaches. This funding opportunity emphasizes the importance of multisite feasibility trials to gather essential data for planning future efficacy studies. Deadlines for standard and AIDS-related applications range from February 2024 to November 2026, underscoring the urgency for innovative research in high-priority areas.

The NIAID aims to enhance infectious disease research by supporting human microphysiologic systems (MPS) development. These in vitro platforms mimic human tissue functions, promoting drug and biological product development while reducing animal use. This initiative aligns with NIH’s commitment to innovative research practices and regulatory acceptance. By focusing on MPS in infectious disease contexts, NIAID seeks to streamline therapeutic advancements and establish robust human tissue models, addressing critical challenges in understanding and treating infections.

The Interdisciplinary Transportation Law and Policy Technology Training Program aims to enhance the skills of policymakers and legal professionals in adapting to rapid advancements in transportation technology, including AI and automated vehicles. This initiative will allocate $600,000 to develop a comprehensive training curriculum, including a week-long course for support staff and a semester-long program for law students. The project will be executed over a 24-month period, targeting University Transportation Centers and their consortia.

The Placement and Coordination Program, administered by the Office of Refugee Resettlement, invites eligible organizations to enhance refugee resettlement services. By diversifying service providers, the program aims to strengthen the national resettlement framework. Key responsibilities include managing the Program of Initial Resettlement and Intensive Case Management for vulnerable refugees, ensuring comprehensive support from arrival through initial resettlement, and addressing barriers to self-sufficiency.

The National Institute of Nursing Research (NINR) plans to publish a funding opportunity announcement for Community-Partnered Nursing Research Centers (P20 Clinical Trial Optional). This initiative aims to strengthen nursing-led programs that foster community-partnered research addressing significant health issues. By enhancing interdisciplinary research capacities, the program will establish centralized resources in nursing schools, build expertise in community partnerships, and support nurse-led teams in developing, implementing, and evaluating impactful research projects.

The NIH R25 program promotes broad participation in the biomedical and behavioral sciences by supporting educational activities. It aims to encourage individuals from diverse and underrepresented backgrounds to engage in research through mentoring networks and research education experiences. This initiative seeks to enhance the workforce by providing opportunities for further study and career advancement in research fields, ultimately contributing to a more inclusive scientific community.

The DoW Ovarian Cancer Pilot Award fosters innovative research that challenges existing paradigms in ovarian cancer. It aims to propel groundbreaking discoveries and advancements in the field. Notably, the award prioritizes originality over scientific merit alone, ensuring that innovative ideas are at the forefront. The application process includes a blinded pre-application screening to maintain confidentiality and integrity, encouraging fresh perspectives in ovarian cancer research.

The FY26 Neurofibromatosis Research Program's Synergistic Idea Award supports innovative research on neurofibromatosis (NF) through collaborative efforts of two or three Principal Investigators (PIs). By leveraging their unique perspectives, these PIs will tackle significant questions in NF research. Applicants must provide relevant preliminary or published data to support their proposals, ensuring a strong foundation for impactful research outcomes.

The DoW Neurofibromatosis Investigator-Initiated Research Award addresses critical needs in neurofibromatosis research, aiming to enhance patient care through innovative projects. It supports various research phases, excluding clinical trials, and encourages collaboration between scientists and clinicians. The funding mechanism includes two levels based on participation in optional features, such as the Open Science Initiative and collaboration with qualified partners, promoting data sharing and collaborative research efforts.

The FY26 Neurofibromatosis Research Academy – Scholar Award supports early-career independent investigators focusing on neurofibromatosis research. Scholars are required to be within 10 years of their terminal degree and must designate a Career Guide for mentorship, fostering collaboration. This initiative aims to advance impactful research and develop skilled researchers in a supportive environment, addressing critical areas of emphasis in neurofibromatosis research.

The FY26 Neurofibromatosis Research Program's Exploration-Hypothesis Development Award encourages innovative, high-risk research concepts in neurofibromatosis (NF). This award aims to support groundbreaking studies that will pave the way for future scientific inquiries. Proposals should present a well-defined, testable hypothesis grounded in sound scientific rationale. While preliminary data is encouraged, it is not a prerequisite for submission, allowing researchers to explore novel paradigms and perspectives in NF research.

The NIH Research Evaluation and Commercialization Hubs (REACH) program aims to facilitate the translation of biomedical discoveries into marketable products to enhance patient care. By funding five new academic entrepreneurship hubs, NIH will provide essential resources such as funding, mentorship, and expertise in product development. These hubs will address high-priority technologies and foster public-private partnerships, ultimately supporting the goals of federal research initiatives and addressing local health needs in underserved areas.

The Ovarian Cancer Research Program (OCRP) Investigator-Initiated Research Award aims to support impactful research addressing critical needs in ovarian cancer and patient care. It requires a robust research plan with preliminary data and allows for studies across all research phases, excluding clinical trials. A unique Partnering Principal Investigator option encourages collaboration between two PIs to enhance research outcomes beyond individual efforts, promoting innovation in the field of ovarian cancer.

The FY26 Breast Cancer Research Program (BCRP) Breakthrough Award Level 3 supports transformative research aimed at significant advancements in breast cancer treatment. Applicants must address key challenges outlined by the program, ensuring their proposals demonstrate potential for impactful breakthroughs. This funding mechanism, which permits small-scale clinical trials, emphasizes collaboration by requiring research teams to include two breast cancer consumer advocates and allows for a single Principal Investigator or two partnering PIs.

The DoW Ovarian Cancer Clinical Trial Award, funded by the U.S. Army Medical Command, aims to accelerate the implementation of clinical trials that significantly impact ovarian cancer treatment. This award supports diverse trial designs, from early proof-of-concept studies to large-scale efficacy trials, evaluating innovative drugs, biologics, and technologies. By fostering research in this critical area, the program seeks to enhance patient outcomes and advance the understanding of ovarian cancer management.

The Ovarian Cancer Clinical Trial Academy (OCCTA) supports Early-Career Investigators (ECIs) in clinical trial research aimed at effective ovarian cancer treatments. It provides essential mentoring, networking, and skill development needed for executing clinical trials. The FY26 funding will specifically support translational research and early-phase trials, requiring preliminary data and a commitment of at least 25% effort from the ECI. Mentorship is vital, with a focus on experienced clinical trialists guiding ECIs.

The DoW Ovarian Cancer Academy Early-Career Investigator Award supports junior faculty in conducting innovative ovarian cancer research. Established in FY09, this unique virtual academy fosters mentorship, collaboration, and networking among Early-Career Investigators (ECIs) and their mentors. Participants engage in monthly webinars and annual workshops, enhancing their research skills while contributing to impactful studies in ovarian cancer. The program aims to cultivate a new generation of highly productive researchers in this critical field.

The FY26 Breast Cancer Research Program (BCRP) Breakthrough Award Level 4 supports innovative research with the potential for significant breakthroughs in breast cancer. Applications must address key BCRP challenges or justify exceptions, focusing on impactful solutions. This program mandates clinical trials and requires participation from breast cancer consumer advocates. The funding supports single or partnered Principal Investigators, ensuring comprehensive submission processes to avoid administrative withdrawal.

This grant opportunity aims to reduce sleep health disparities through non-pharmacological interventions. It supports research that examines sleep as a modifiable factor influencing health outcomes among populations facing health disparities. The initiative highlights the importance of promoting sleep health in various communities, ensuring equitable access to resources and interventions. Deadlines for applications span from October 2024 to June 2027, allowing multiple opportunities for researchers to apply and contribute to this vital area of health research.

The NCI Worta McCaskill-Stevens Career Development Award supports new clinicians committed to research in community oncology and cancer prevention. This funding aims to facilitate their transition to independent research careers and advanced funding mechanisms. Scholars can lead independent community-based clinical trials, conduct ancillary studies, or gain valuable research experience, specifically targeting underserved communities. Applications are due by 5:00 PM local time of the applicant's organization.

The Forecast for Clinical Trial Readiness for Rare Diseases (R21) aims to enhance the development and testing of diagnostics and therapeutics for rare diseases. This funding opportunity invites researchers to facilitate clinical trial readiness by developing rigorous biomarkers and clinical outcome measures. Through collaborative efforts with various stakeholders, NCATS seeks to improve the efficiency of moving candidate therapeutics towards clinical trials, ultimately increasing the likelihood of successful treatments for rare diseases.

The Fetal, Infant, and Child Death Review Program aims to enhance the effectiveness of fetal, infant, and child death review teams across state, local, and tribal levels. By providing essential leadership and technical assistance, the program ensures standardized practices for conducting quality fatality reviews and collecting vital data. These efforts will facilitate the dissemination of findings, ultimately informing prevention strategies and improving outcomes for vulnerable populations.

The Procter & Gamble U.S. Large Site Community Grant supports initiatives that enhance the lives of individuals within 50 miles of P&G facilities. Focused on areas like infant development and hygiene, this competitive grant seeks to partner with organizations aligned with its mission. Interested groups should verify eligibility through the P&G grant portal. While many applications are received, only a select few will be funded due to high demand.

The Ryan White HIV/AIDS Program Part B AIDS Drug Assistance Program Training and Technical Assistance aims to enhance the capacity of ADAPs. By providing essential tools and expert guidance, the program seeks to improve health outcomes for individuals living with HIV in an evolving healthcare landscape. This initiative is funded by the US HHS through the Health Resources & Services Administration, ensuring support and resources are effectively allocated to meet the needs of vulnerable populations.

The Fertility Grants (VIVA Program) by the Bob Woodruff Foundation offer vital financial support to wounded veterans facing infertility challenges due to their service-related conditions. Since its inception, the program has assisted over 100 veteran families in starting their own, highlighting a commitment to ensuring veterans have access to necessary fertility treatments. This initiative addresses the unique needs of veterans, recognizing that they experience infertility at nearly double the rate of the general population.